UniQure Gene Therapy Slows Huntington's Disease Progression for Four Years

Huntington's disease is a devastating inherited neurodegenerative condition that progressively destroys brain cells, robbing patients of movement, cognition, and ultimately life. There is currently no disease-modifying treatment approved for it. UniQure's AMT-130 represents a novel one-time gene therapy approach, surgically implanted directly into the brain to silence the mutant huntingtin gene responsible for the disease.

In the latest analysis, patients who received a high dose of AMT-130 showed 44% slower disease progression compared to a matched external control group derived from a large natural history study. This is a meaningful signal for a disease with no existing treatment options, suggesting the gene therapy continues to exert a biological effect four years after a single administration.

However, the magnitude of benefit has declined compared to results reported approximately one year ago. This attenuation raises important questions about whether the therapy's protective effect is durable over the long term, or whether the silencing of the huntingtin gene becomes less complete over time. Critically, the 44% reduction in progression did not reach statistical significance, which complicates interpretation.

The timing is significant because the FDA has begun reviewing UniQure's marketing application for AMT-130. A weakening benefit signal, paired with a lack of statistical significance, could prompt regulators to request additional data or impose stricter conditions on any approval.

For longevity and brain health researchers, this trial remains one of the most closely watched gene therapy programs targeting neurodegeneration. The ability to deliver a one-time intervention that meaningfully alters the course of a progressive brain disease — even with caveats — is a landmark proof of concept that may inform future gene therapies for other age-related neurodegenerative conditions such as Alzheimer's and Parkinson's disease.